Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Product Details

Additional Information about Patents

• Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
• Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
• As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N204370

Product 001
CARIPRAZINE HYDROCHLORIDE (VRAYLAR) CAPSULE EQ 1.5MG BASE

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	7737142	09/17/2029	DS	DP	U-1750 U-2543 U-2544 U-2545 U-3503		10/16/2015
001	7943621	12/16/2028	DS	DP			10/16/2015
001	RE47350	07/16/2029			U-1750 U-2543 U-2544 U-2545 U-3503		05/15/2019
001	RE49110	07/16/2029			U-2543 U-2544 U-2545 U-3503		07/21/2022
001	RE49302	07/16/2029			U-2543 U-2544 U-2545 U-3503		01/13/2023

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
001	I-904	12/16/2025

 

 

View a list of all patent use codes
View a list of all exclusivity codes